Bedrijfsoverzicht
Decoy Therapeutics Inc. is a specialized biotechnology enterprise dedicated to advancing peptide conjugate therapeutics via its proprietary Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology, known as the IMP3ACT platform. This platform is engineered to reduce the inherent complexity associated with drug development and manufacturing processes, leveraging machine learning and artificial intelligence to optimize these stages. The company operates within the healthcare sector, specifically categorized under the biotechnology industry, which focuses on the discovery, development, and commercialization of biological treatments. With a market capitalization of $3.11 million and an employee count of 11, Decoy Therapeutics represents a micro-cap entity with a very limited operational footprint. The combination of a sub-$4 million market cap and the absence of reported annual revenue indicates that the company is in an early-stage development phase, relying on potential future product approvals rather than current commercial sales to generate value.
Financiële gezondheid
The company's financial statements for the trailing twelve months reveal a revenue of N/A, a net income of $-12,518,480, and an EBITDA of $-4,088,835, highlighting a significant gap between top-line activity and bottom-line profitability. This substantial discrepancy between revenue (which is not applicable or negligible in the traditional sense for a pre-revenue biotech) and net income underscores a cost structure heavily weighted toward research, development, and operational overheads typical of early-stage life sciences firms. Despite the reported net losses, the company reports free cash flow of $1.82M, which provides a crucial buffer for financial flexibility by allowing management to fund operations without immediate external capital injections. The gross margin stands at 0.0%, the operating margin at 0.0%, and the profit margin at 0.0%, reflecting the accounting treatment of development costs as expenses prior to commercialization rather than as cost of goods sold. In terms of liquidity, the company holds $10.71M in cash against $0 in debt, creating a highly conservative balance sheet with no leverage and zero debt-to-equity ratio. The current ratio of 2.13 indicates that the company possesses more than double the current assets relative to current liabilities, suggesting robust short-term liquidity and the ability to meet obligations as they come due. Furthermore, the return on equity is -338.3% and the return on assets is -36.4%, metrics that reveal that management is currently deploying capital to generate losses rather than profits, a common characteristic of companies investing heavily in pipeline assets before achieving commercial milestones.
Waarderingsbeoordeling
The valuation metrics for Decoy Therapeutics present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of -0.30. The distinction between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in future earnings potential that has not yet been realized, making traditional price-to-earnings comparisons with profitable peers inapplicable. The price-to-book ratio is 0.53, indicating that the market values the company at approximately half of its net asset book value, which often suggests the market is discounting the firm's intangible assets like intellectual property and pipeline potential. Since revenue is N/A, the price-to-sales ratio is also N/A, while the EV/EBITDA stands at 1.86, offering an alternative valuation lens that suggests the company's enterprise value relative to its earnings before interest, taxes, depreciation, and amortization is relatively low on a multiple basis. The stock has experienced extreme volatility, trading between a 52-week high of $415.80 and a 52-week low of $5.40. Assuming a current trading price near the lower end of the recent range given the beta context, the stock trades significantly below its 52-week high, reflecting the high risk premium demanded by investors for speculative biotech assets. The beta value of 0.36 suggests that the stock's price volatility is less than 36% of the broader market's movement, indicating a low correlation with general market swings despite its high individual risk profile.
Growth & Income
The reported revenue growth year-over-year is N/A, and earnings growth year-over-year is also N/A, rendering direct comparisons of growth rates impossible due to the lack of historical financial data in the trailing twelve months. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests all available resources, including its substantial cash reserves, into research and development rather than distributing income to shareholders. The absence of a dividend policy is consistent with the company's stage of development, where capital retention is prioritized for advancing the IMP3ACT platform and reducing the complexity of drug manufacturing. Consequently, the overall growth and income profile is defined entirely by the potential future success of its biotechnology pipeline rather than current cash generation or shareholder distributions.